Prognostic value of serum and dialysate APX-501 in chronic dialysis

Jin Joo Cha1, Jung Hwan Lee2, Jung Pyo Lee2, Jong Hyun Lee4, Seun Duk Hwang4, Dong Young Lee5, Hyung Ah Jo3, Sang Youb Han3, Dae Ryong Cha1
1Department of Internal Medicine-Nephrology, Korea University Ansan Hospital, Korea, Republic of
2Department of Internal Medicine-Nephrology, SMG-SNU Boramae Medical Center, Korea, Republic of
3Department of Internal Medicine-Nephrology, Inje University Ilsan Paik Hospital, Korea, Republic of
4Department of Internal Medicine-Nephrology, Inha University Hospital, Korea, Republic of
5Department of Internal Medicine-Nephrology, Seoul Veterans Hospital, Korea, Republic of

Objectives: Patients on chronic dialysis are known to be in a chronic inflammation associated with increased oxidative injury, which results in increased morbidity and mortality Recently APX-501 protein was identified to have regulatory role on oxidative stress. In the present study, we examined the clinical utility of APX-501 levels in serum and dialysate in chronic dialysis patients.

Methods: This study was a multicenter, prospective study that examined the level of serum and dialysate APX-501 in patients on chronic dialysis. Patients on dialysis (both peritoneal and hemodialysis) were enrolled between January 2016 to February 2018. Serum APX-501 level was measured using ELISA method. During follow up period of 625±172.8 days, time to overall mortality was recorded as the primary endpoint. For secondary endpoint, admission for major adverse cardiac events (MACE) and admission due to infection were recorded. Kaplan-Meier analysis was performed.

Results: Of 216 patients, patient on PD consisted of 136 patients. 37.5% of PD patients were enrolled initiating PD as the first dialysis modality (defined as new PD). During the follow up period, 15 patients died (6.9%), 27 experienced MACE (12.5%), 64 admitted to the hospital for infection from any cause (29.6%) and PD peritonitis was reported in 35 patients (25.7% of PD group, of which 17(48.6%) were in new PD group). For PD patients who had higher level of baseline dialysate APX-501 level, showed significant increased risk of incidence on infection from any cause (log rank p=0.024) and PD peritonitis (log rank p= 0.026).

Conclusions: Dialysate APX-501 level may predict the risk of infection, especially the risk of PD peritonitis in PD patients, but not the serum APX-501 level. Studies for predictability for imminent PD peritonitis should be ensued.